BioWorld - Monday, December 8, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: ASH 2025: Casgevy for kids? Expanding, improving SCD gene therapiesBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector

BioWorld Science, Endocrine/metabolic
BioWorld Science, Endocrine/metabolic RSS Feed RSS

Endocrine/metabolic

CRF1 and CRF2 antagonists disclosed in Neurocrine Biosciences patent

July 10, 2025
Neurocrine Biosciences Inc. has divulged cyclic peptides acting as corticotropin-releasing factor 1 and 2 (CRF1 and CRF2) antagonists reported to be useful for the treatment of congenital adrenal hyperplasia, cancer, osteoporosis, myopathy, hyperglycemia, Cushing syndrome, peptic ulcers and hypertension, among others.
Read More
Endocrine/metabolic

Guangdong Zhongsheng Ruichuang Pharmaceutical discovers new GLP-1R agonists

July 9, 2025
Guangdong Zhongsheng Ruichuang Pharmaceutical Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), hyperglycemia, cerebral infarction, hypertension and Parkinson’s disease.
Read More
Liver over digital lens background
Endocrine/metabolic

MWN-105 ameliorates MASH symptoms in the preclinical setting

July 9, 2025
No Comments
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that has limited available therapies. Shanghai Minwei Biotechnology Co. Ltd. has developed and presented data for MWN-105, a GLP-1/GIP/FGF21 triple agonist aimed at controlling metabolic dysfunction and fibrosis during MASH.
Read More
Peptide illustration
Endocrine/metabolic

Insparin, a promising antidiabetic peptide

July 4, 2025
No Comments
Insparin is a protein isolated from human adenovirus Ad36 that induces cellular glucose uptake without impacting safety. A preclinical study of insparin looked at its potential antidiabetic effects compared to those of pioglitazone.
Read More
Pills, bottle, scale and-measuring tape
Endocrine/metabolic

Eccogene’s ECC-4703 leads to greater weight loss in preclinical studies

July 3, 2025
No Comments
Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an agonist of thyroid hormone receptor β (THR-β) and its metabolic impact on preclinical models of obesity in combination with semaglutide was investigated.
Read More
Man measuring waist
Endocrine/metabolic

BI-4659 reverses diet-induced obesity in mice

July 1, 2025
No Comments
Therapies based on glucagon-like peptide 1 (GLP-1) are the most effective for treating obesity to date, but their efficacy and tolerability are limited by gastrointestinal side effects and compensatory reduction of energy expenditure.
Read More